Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista Cubana de Medicina Militar
versión impresa ISSN 0138-6557versión On-line ISSN 1561-3046
Resumen
CORREA JAUREGUI, Manuel. The inhibitors of the phosphodiesterases in treatment of erectile sexual dysfunction. Rev Cub Med Mil [online]. 2010, vol.39, n.3-4, pp.255-264. ISSN 0138-6557.
The male sexual dysfunction imposes a significantly negative burden in health, in the interpersonal relations, in self-esteem, and the quality of life of those suffering it. Up to at the end of the 80 decade, treatment was limited to psychosexual therapy and to penile implants and the cause was due to mainly to psychological factors. The appearance of oral inhibitors of phosphodiesterase-5 like the Sildenafil citrate (Viagra) in1998, was from its onsets a real revolution and now are the first choice for treatment of erectile dysfunction because it is well tolerated, effective, non-invasive and with a good response rate. In present paper authors made a review of the use of phosphodiesterases inhibitors in treatment of the erectile sexual dysfunction, as well as the relevant features of the drugs nowadays more used contributing to its knowledge and its prescription. The aim of present paper was to look for the more updated papers published in Pubmed and Medline. Phosphodiesterase inhibitors (Sildenafil, Vardenafil and Tadalafil) are the choice drugs in treatment of erectile dysfunction due to its demonstrated effectiveness, safety and tolerance.
Palabras clave : Erectile sexual dysfunction; phosphodiesterase-5; nitric oxide.